AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

674.765

-1.599-0.24%

Number of Gainers:5

Number of Losers:12

Number of Flat:26

PE:- -

High:685.239

Open:680.163

Low:670.162

Close:676.364

Volume:17.07M

Turnover:46.84M

Market Cap:96.98B

Float Cap:93.86B

Loading ...

Cynata Therapeutics Terminates of At-the-Market Subscription Deed

Imricor Medical Systems Says FDA Completes Review of PMA Module Three

MT Newswires Live

Imricor Medical Systems - FDA Completes Review of Imricor's Third Pma Module

THOMSON REUTERS

Imricor Medical Systems - no Deficiencies Identified for Vision-Mr Ablation Catheter 2.0

THOMSON REUTERS

Imricor Medical Systems - Preparing Response to FDA for Module 3 Closure

THOMSON REUTERS

Cynata Therapeutics Ltd - Termination of At

THOMSON REUTERS

Noxopharm Ltd-FDA Feedback Supports Sof-Skn Phase Ii Plans

THOMSON REUTERS

ASX Growth Stocks With High Insider Ownership October 2026

Simply Wall St.

Citi Raises CSL's PT After $1.6 Billion Alentis Deal

CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds

Simply Wall St.

3 Australian Biotech Stocks With At Least 64% Fair Value Upside

Simply Wall St.

DroneShield And 2 Australian Penny Stocks To Watch

Simply Wall St.

CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says

MT Newswires Live

Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon

THOMSON REUTERS

Settlement of Notes Expected on October 14, 2026

THOMSON REUTERS

CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds

THOMSON REUTERS

Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon

THOMSON REUTERS

Notes to be Issued by Cslb. and Guaranteed by CSL

THOMSON REUTERS

Proceeds to be Used to Refinance Debt and for General Corporate Purposes

THOMSON REUTERS

Imugene Ltd-DR John Le Gall Appointed Chief Medical Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":674.7649,"timestamp":1791423452747,"preClose":676.3637,"halted":0,"volume":17074838,"delay":0,"changeRate":-0.002364,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-1.598816,"latestTime":"10-08 12:37:37 AEDT","open":680.1626,"high":685.2389,"low":670.1617,"amount":46835366,"amplitude":0.022292,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791414000000,1791435600000]],"turnoverRate":0.000679,"increases":7,"decrements":12,"flats":23,"marketCap":96978183034.75,"floatMarketCap":93855939539.375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":685.2389,"amplitude":0.022292,"preClose":676.3637,"low":670.1617,"latestPrice":674.7649,"volume":17074838,"delay":0,"open":680.1626,"prevYearClose":644.3692,"prevWeekClose":654.21,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":666.631,"twentyDayClose":646.103,"sixtyDayClose":495.646,"secType":"PLATE","market":"AU","turnoverRate":0.000679,"marketCap":96978183034.75,"floatMarketCap":93855939539.375,"timestamp":1791423452747,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":5,"down":12,"flat":26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673049962","title":"Cynata Therapeutics Terminates of At-the-Market Subscription Deed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673049962?lang=en_us&edition=fundamental","pubTime":"2026-10-08 08:51","pubTimestamp":1791420662,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Terminates Of At-The-Market Subscription DeedOct 8 (Reuters)-Cynata Therapeutics LtdCYP.AX:TERMINATION OF AT--MARKET SUBSCRIPTION DEEDFurther company coverage:CYP.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673046364","title":"Imricor Medical Systems Says FDA Completes Review of PMA Module Three","url":"https://stock-news.laohu8.com/highlight/detail?id=2673046364","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673046364?lang=en_us&edition=fundamental","pubTime":"2026-10-08 07:41","pubTimestamp":1791416498,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  said the US Food and Drug Administration has completed its review of module three of the company's premarket approval  submission, which covers non-clinical bench testing for its Vision-MR ablation catheter 2.0, RF-5000 system and irrigation tubing set, according to a Thursday Australian bourse filing.No deficiencies were identified in the catheter or tubing set, while one deficiency was found in the RF-5000 system's third-party software operating system, which the company has already upgraded to a long-term supported version, per the filing.The company is preparing its response to the FDA, with module three expected to close upon acceptance and module four targeted for submission in November, thereby completing all PMA submissions, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7007","BK7503","LABU","PMA","BK4585","IMR.AU","BK4588","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673430360","title":"Imricor Medical Systems - FDA Completes Review of Imricor's Third Pma Module","url":"https://stock-news.laohu8.com/highlight/detail?id=2673430360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673430360?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:18","pubTimestamp":1791411483,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7503","BK7007","BK7508","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043039","title":"Imricor Medical Systems - no Deficiencies Identified for Vision-Mr Ablation Catheter 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043039?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:18","pubTimestamp":1791411483,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7503","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673031043","title":"Imricor Medical Systems - Preparing Response to FDA for Module 3 Closure","url":"https://stock-news.laohu8.com/highlight/detail?id=2673031043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673031043?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:18","pubTimestamp":1791411483,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7503","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673304353","title":"Cynata Therapeutics Ltd - Termination of At","url":"https://stock-news.laohu8.com/highlight/detail?id=2673304353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673304353?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:27","pubTimestamp":1791408469,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043831","title":"Noxopharm Ltd-FDA Feedback Supports Sof-Skn Phase Ii Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043831?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:15","pubTimestamp":1791407737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUEC8TCQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NOX.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017001","title":"ASX Growth Stocks With High Insider Ownership October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017001?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:08","pubTimestamp":1791400080,"startTime":"0","endTime":"0","summary":"As the Australian market prepares for a potentially positive start to the week, investor sentiment remains cautious amid concerns over rising bond yields and geopolitical factors. In this environment, growth companies with high insider ownership can be appealing as they often reflect strong confidence from those closest to the business.","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-stocks-with-high-insider-ownership-october-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-stocks-with-high-insider-ownership-october-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7142","BK7017","BK7104","XAO.AU","QFN.AU","IOZ.AU","IISV.AU","GEAR.AU","BK7096","PDI.AU","VAS.AU","XKO.AU","BK7093","EIGA.AU","OZF.AU","QRE.AU","WZR.AU","DVP.AU","OZR.AU","BK7110","IMLC.AU","P1E.AU","AR1.AU","BEAR.AU","STW.AU","AEM.AU","E200.AU","ZYAU.AU","BBOZ.AU","BK7095","GIVE.AU","BK7068","SKS.AU","BK7504","LTR.AU","SPL.AU","IIGF.AU","BGD.AU","FRS.AU","BK7016","BK7508","BK7023","VAP.AU","AV1.AU","SLF.AU","XJO.AU","DDR.AU","DACE.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017859","title":"Citi Raises CSL's PT After $1.6 Billion Alentis Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017859?lang=en_us&edition=fundamental","pubTime":"2026-10-08 02:43","pubTimestamp":1791398609,"startTime":"0","endTime":"0","summary":"BUZZ-Citi raises CSL's PT after $1.6 billion Alentis deal** Citi raises PT of Australia's CSLCSL.AXto A$180, sees upside in deal with Alentis** On Monday, the biotech giantsignedan agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion** Brokerage says the deal is consistent and structurally sound aligning with company commentary** Says deal sticks within an area CSL already operates - orphan renal conditions** Sees $125 million risk adjusted sales by 2031, addresses that pipeline replenishment is a key concern for investors and sees this as a positive step** 10 of 17 analysts rate the stock \"buy\" or higher, seven \"hold\"; their median PT is A$182, LSEG-compiled data shows** YTD, stock up nearly 5.5%, as of last close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T14G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673019013","title":"CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673019013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673019013?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:38","pubTimestamp":1791383882,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has entered into an exclusive partnership with Alentis Therapeutics to co-develop lixudebart, supporting the antibody with a US$355 million upfront payment and up to US$1.2 billion in potential milestone payments.\nCSL shares have been on a strong run recently, with the 90 day share price return of 44.98% and 30 day share price return of 5.09% suggesting momentum has picked up after a weaker patch. This comes even though the 1 year total shareholder return is still down 9.23% and...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7511","BK7508","ISBC","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011506","title":"3 Australian Biotech Stocks With At Least 64% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011506","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011506?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:48","pubTimestamp":1791373688,"startTime":"0","endTime":"0","summary":"IMF warnings about high public debt and the risks around rapid AI investment have pushed many investors to look for sectors where real science backs the story. Australian biotech stocks fit that brief, with businesses built around research pipelines rather than hype. For investors willing to handle higher risk, this corner of the market can be compelling. This article highlights three stocks from our biotech screen that may warrant closer examination.\nThe three biotech stocks below are only a...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VAS.AU","GEAR.AU","VLS.AU","DACE.AU","IMLC.AU","IOZ.AU","BK4585","SLF.AU","BK7508","VAP.AU","QFN.AU","XBIX","BEAR.AU","IIGF.AU","XJO.AU","AIPO","ZYAU.AU","BK4588","NVIB","BK7096","OZF.AU","QRE.AU","GIVE.AU","XBI","CUV.AU","BBOZ.AU","IISV.AU","BK7067","STW.AU","XAO.AU","OZR.AU","E200.AU","EIGA.AU","XKO.AU","MYX.AU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673190990","title":"DroneShield And 2 Australian Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2673190990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673190990?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:48","pubTimestamp":1791373682,"startTime":"0","endTime":"0","summary":"AI is now shaping global growth expectations, and the IMF is warning that the benefits are flowing to a narrow group of markets. That kind of concentration can leave overlooked Australian small caps looking especially interesting. Financially solid low priced companies give you exposure to early stage growth stories without only chasing the crowded AI trade. This article highlights three financially disciplined penny stocks that meet those criteria.\nThe three stocks covered below are just a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice2-card/1788948713663","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice2-card/1788948713663"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/droneshield-and-2-australian-penny-stocks-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/droneshield-and-2-australian-penny-stocks-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLF.AU","XAO.AU","BK7115","DRO.AU","BK7508","GEAR.AU","IOZ.AU","BBOZ.AU","OZR.AU","STW.AU","XKO.AU","XJO.AU","IISV.AU","GIVE.AU","OZF.AU","VAP.AU","ZYAU.AU","IIGF.AU","MSB.AU","QFN.AU","BK7083","BK7501","DACE.AU","VAS.AU","QRE.AU","BOE.AU","BEAR.AU","EIGA.AU","IMLC.AU","BK7067","E200.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673671490","title":"CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673671490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673671490?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:10","pubTimestamp":1791346251,"startTime":"0","endTime":"0","summary":"CSL's  deal with Alentis Therapeutics for Lixudebart, a therapy candidate for anti-neutrophil cytoplasmic antibodies-associated vasculitis and rapidly progressive glomerulonephritis, is low-risk but low-reward, RBC Capital Markets said in a Thursday note.It noted that the clinical and commercial aspects of Lixudebart are unknown and the timeframe to first potential commercial revenues is fairly long. The deal's PoS adjusted net present value is AU$415 million.RBC reduced CSL's earnings per share forecasts by 0.1% to 0.4% for fiscal 2027 to fiscal 2029.The brokerage assigned an outperform rating to CSL and raised the price target to AU$215 from AU$213.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0029864427.USD","LU0310800379.SGD","LU0708994859.HKD","LU1267930573.SGD","GSIB","BK7501","BK4207","CSL.AU","LU0128525929.USD","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673662090","title":"Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673662090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673662090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673306620","title":"Settlement of Notes Expected on October 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673306620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673306620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673208066","title":"CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673208066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673208066?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066270","title":"Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066270?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066206","title":"Notes to be Issued by Cslb. and Guaranteed by CSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066206?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7501","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066205","title":"Proceeds to be Used to Refinance Debt and for General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066205?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066421","title":"Imugene Ltd-DR John Le Gall Appointed Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066421?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:18","pubTimestamp":1791325117,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE7BLDWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}]}}